Global Malignant Mesothelioma Drugs Market Size, Status, Research and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 102

Report ID: 3697

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of mesothelioma drugs by governments to ensure availability in hospital pharmacies and oncology centers.
In 2018, the global Malignant Mesothelioma Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Malignant Mesothelioma Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Malignant Mesothelioma Drugs development in United States, Europe and China.

The key players covered in this study
AstraZeneca
Bristol-Myers Squibb
Roche
Merck
Novartis
Pfizer
Sanofi
Eli Lilly
Teva Pharmaceuticals
Boehringer Ingelheim GmbH
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Corden Pharma
Concordia International
Kyowa Hakko Kirin
Polaris Pharmaceuticals
MolMed
Ono Pharmaceutical
Nichi-Iko Pharmaceutical

Market segment by Type, the product can be split into
Pemetrexed
Cisplatin
Carboplatin
Gemcitabine
Vinorelbine
Other

Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Oncology Centers
Other

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Malignant Mesothelioma Drugs status, future forecast, growth opportunity, key market and key players.
To present the Malignant Mesothelioma Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Malignant Mesothelioma Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Malignant Mesothelioma Drugs Market Size Growth Rate by Type (2014-2025)
1.4.2 Pemetrexed
1.4.3 Cisplatin
1.4.4 Carboplatin
1.4.5 Gemcitabine
1.4.6 Vinorelbine
1.4.7 Other
1.5 Market by Application
1.5.1 Global Malignant Mesothelioma Drugs Market Share by Application (2014-2025)
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Oncology Centers
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Malignant Mesothelioma Drugs Market Size
2.2 Malignant Mesothelioma Drugs Growth Trends by Regions
2.2.1 Malignant Mesothelioma Drugs Market Size by Regions (2014-2025)
2.2.2 Malignant Mesothelioma Drugs Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Malignant Mesothelioma Drugs Market Size by Manufacturers
3.1.1 Global Malignant Mesothelioma Drugs Revenue by Manufacturers (2014-2019)
3.1.2 Global Malignant Mesothelioma Drugs Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Malignant Mesothelioma Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Malignant Mesothelioma Drugs Key Players Head office and Area Served
3.3 Key Players Malignant Mesothelioma Drugs Product/Solution/Service
3.4 Date of Enter into Malignant Mesothelioma Drugs Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Malignant Mesothelioma Drugs Market Size by Type (2014-2019)
4.2 Global Malignant Mesothelioma Drugs Market Size by Application (2014-2019)

5 United States
5.1 United States Malignant Mesothelioma Drugs Market Size (2014-2019)
5.2 Malignant Mesothelioma Drugs Key Players in United States
5.3 United States Malignant Mesothelioma Drugs Market Size by Type
5.4 United States Malignant Mesothelioma Drugs Market Size by Application

6 Europe
6.1 Europe Malignant Mesothelioma Drugs Market Size (2014-2019)
6.2 Malignant Mesothelioma Drugs Key Players in Europe
6.3 Europe Malignant Mesothelioma Drugs Market Size by Type
6.4 Europe Malignant Mesothelioma Drugs Market Size by Application

7 China
7.1 China Malignant Mesothelioma Drugs Market Size (2014-2019)
7.2 Malignant Mesothelioma Drugs Key Players in China
7.3 China Malignant Mesothelioma Drugs Market Size by Type
7.4 China Malignant Mesothelioma Drugs Market Size by Application

8 Japan
8.1 Japan Malignant Mesothelioma Drugs Market Size (2014-2019)
8.2 Malignant Mesothelioma Drugs Key Players in Japan
8.3 Japan Malignant Mesothelioma Drugs Market Size by Type
8.4 Japan Malignant Mesothelioma Drugs Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Malignant Mesothelioma Drugs Market Size (2014-2019)
9.2 Malignant Mesothelioma Drugs Key Players in Southeast Asia
9.3 Southeast Asia Malignant Mesothelioma Drugs Market Size by Type
9.4 Southeast Asia Malignant Mesothelioma Drugs Market Size by Application

10 India
10.1 India Malignant Mesothelioma Drugs Market Size (2014-2019)
10.2 Malignant Mesothelioma Drugs Key Players in India
10.3 India Malignant Mesothelioma Drugs Market Size by Type
10.4 India Malignant Mesothelioma Drugs Market Size by Application

11 Central & South America
11.1 Central & South America Malignant Mesothelioma Drugs Market Size (2014-2019)
11.2 Malignant Mesothelioma Drugs Key Players in Central & South America
11.3 Central & South America Malignant Mesothelioma Drugs Market Size by Type
11.4 Central & South America Malignant Mesothelioma Drugs Market Size by Application

12 International Players Profiles
12.1 AstraZeneca
12.1.1 AstraZeneca Company Details
12.1.2 Company Description and Business Overview
12.1.3 Malignant Mesothelioma Drugs Introduction
12.1.4 AstraZeneca Revenue in Malignant Mesothelioma Drugs Business (2014-2019)
12.1.5 AstraZeneca Recent Development
12.2 Bristol-Myers Squibb
12.2.1 Bristol-Myers Squibb Company Details
12.2.2 Company Description and Business Overview
12.2.3 Malignant Mesothelioma Drugs Introduction
12.2.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Drugs Business (2014-2019)
12.2.5 Bristol-Myers Squibb Recent Development
12.3 Roche
12.3.1 Roche Company Details
12.3.2 Company Description and Business Overview
12.3.3 Malignant Mesothelioma Drugs Introduction
12.3.4 Roche Revenue in Malignant Mesothelioma Drugs Business (2014-2019)
12.3.5 Roche Recent Development
12.4 Merck
12.4.1 Merck Company Details
12.4.2 Company Description and Business Overview
12.4.3 Malignant Mesothelioma Drugs Introduction
12.4.4 Merck Revenue in Malignant Mesothelioma Drugs Business (2014-2019)
12.4.5 Merck Recent Development
12.5 Novartis
12.5.1 Novartis Company Details
12.5.2 Company Description and Business Overview
12.5.3 Malignant Mesothelioma Drugs Introduction
12.5.4 Novartis Revenue in Malignant Mesothelioma Drugs Business (2014-2019)
12.5.5 Novartis Recent Development
12.6 Pfizer
12.6.1 Pfizer Company Details
12.6.2 Company Description and Business Overview
12.6.3 Malignant Mesothelioma Drugs Introduction
12.6.4 Pfizer Revenue in Malignant Mesothelioma Drugs Business (2014-2019)
12.6.5 Pfizer Recent Development
12.7 Sanofi
12.7.1 Sanofi Company Details
12.7.2 Company Description and Business Overview
12.7.3 Malignant Mesothelioma Drugs Introduction
12.7.4 Sanofi Revenue in Malignant Mesothelioma Drugs Business (2014-2019)
12.7.5 Sanofi Recent Development
12.8 Eli Lilly
12.8.1 Eli Lilly Company Details
12.8.2 Company Description and Business Overview
12.8.3 Malignant Mesothelioma Drugs Introduction
12.8.4 Eli Lilly Revenue in Malignant Mesothelioma Drugs Business (2014-2019)
12.8.5 Eli Lilly Recent Development
12.9 Teva Pharmaceuticals
12.9.1 Teva Pharmaceuticals Company Details
12.9.2 Company Description and Business Overview
12.9.3 Malignant Mesothelioma Drugs Introduction
12.9.4 Teva Pharmaceuticals Revenue in Malignant Mesothelioma Drugs Business (2014-2019)
12.9.5 Teva Pharmaceuticals Recent Development
12.10 Boehringer Ingelheim GmbH
12.10.1 Boehringer Ingelheim GmbH Company Details
12.10.2 Company Description and Business Overview
12.10.3 Malignant Mesothelioma Drugs Introduction
12.10.4 Boehringer Ingelheim GmbH Revenue in Malignant Mesothelioma Drugs Business (2014-2019)
12.10.5 Boehringer Ingelheim GmbH Recent Development
12.11 Mylan
12.12 Fresenius Kabi
12.13 Sun Pharmaceuticals
12.14 Corden Pharma
12.15 Concordia International
12.16 Kyowa Hakko Kirin
12.17 Polaris Pharmaceuticals
12.18 MolMed
12.19 Ono Pharmaceutical
12.20 Nichi-Iko Pharmaceutical

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details